In conclusion, using a combination of CEA, CA211, NSE, SCC, and CA199 lung cancer biomarkers, we created a straightforward predictive model that could distinguish between benign and malignant lung disease after LDCT. This evidence concerns the gene CEACAM5 and lung carcinoma.